Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy

Scand J Infect Dis. 2004;36(10):767-9. doi: 10.1080/00365540410021081.

Abstract

Mucormycosis is a rare, but severe, complication in allogenic bone-marrow recipients with a mortality rate of about 80%. Moreover, its incidence appears to have increased within the last decade. We report a case of pulmonary and nasal mucormycosis in a 55-y-old patient, which occurred 1 y after BMT. Treatment combining 4 months of amphotericin B, early surgical resection of infected tissue and discontinuation of immunosuppressive treatment allowed the cure of this mould infection.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / administration & dosage
  • Bone Marrow Transplantation / adverse effects*
  • Bone Marrow Transplantation / methods
  • Combined Modality Therapy
  • Debridement / methods
  • Follow-Up Studies
  • Humans
  • Lung Diseases, Fungal / diagnosis*
  • Lung Diseases, Fungal / therapy*
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / therapy*
  • Male
  • Middle Aged
  • Mucormycosis / diagnosis*
  • Mucormycosis / therapy*
  • Risk Assessment
  • Severity of Illness Index
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome

Substances

  • Amphotericin B